Buy Rating for Praxis Precision Medicines Driven by Promising FDA Progress and Positive Study Outcomes

LifeSci Capital analyst Francois Brisebois has maintained their bullish stance on PRAX stock, giving a Buy rating today.

Francois Brisebois has given his Buy rating due to a combination of factors surrounding Praxis Precision Medicines’ promising development path and regulatory alignment. The company has achieved significant progress with the FDA, particularly regarding the EMBOLD study for Relutrigine, which has been granted Breakthrough Therapy Designation. The FDA’s agreement to an interim analysis in the fourth quarter of 2025 provides a potential acceleration for the NDA submission to early 2026, contingent on positive results.
Moreover, the positive data from the EMBOLD Cohort 1, which showed a statistically significant reduction in seizure frequency, adds confidence to the ongoing Cohort 2 study, making it appear less risky. The anticipated NDA submission for Ulixacaltamide, following successful Phase 3 data, further strengthens the company’s prospects. These developments, along with the expectation of a robust interim readout, have led to an increased price target and a Buy rating for PRAX.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $232.00 price target.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRAX in relation to earlier this year.